Forty Seven
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Forty Seven and buy or sell other stocks, ETFs, and their options commission-free!About FTSV
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities.
CEOMark A. McCamish, MD, PhD
CEOMark A. McCamish, MD, PhD
Employees—
Employees—
HeadquartersMenlo Park, California
HeadquartersMenlo Park, California
Founded2014
Founded2014
Employees—
Employees—
FTSV Key Statistics
Market cap4.60B
Market cap4.60B
Price-Earnings ratio-38.73
Price-Earnings ratio-38.73
Dividend yield—
Dividend yield—
Average volume1.26M
Average volume1.26M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$95.52
52 Week high$95.52
52 Week low$5.53
52 Week low$5.53
Stock Snapshot
With a market cap of 4.6B, Forty Seven(FTSV) trades at $95.51. The stock has a price-to-earnings ratio of -38.73.
On 2025-12-15, Forty Seven(FTSV) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Forty Seven(FTSV) stock has reached 0, versus its average volume of 1.26M.
The stock's 52-week range extends from a low of $5.53 to a high of $95.52.
The stock's 52-week range extends from a low of $5.53 to a high of $95.52.